Financial Performance & Growth - Catalyst Pharmaceuticals experienced a 43.6% increase in total net product revenue in 1Q25 compared to 1Q24[55] - The company's 1Q25 net product revenues reached $141.4 million, up from $98.4 million in 1Q24[61] - Net income (GAAP) for 1Q25 was $56.7 million, significantly higher than the $23.3 million reported in 1Q24[61] - Catalyst forecasts total revenues between $545 million and $565 million for the full year 2025[60] Product Portfolio - FIRDAPSE revenue for 1Q25 was $83.7 million, compared to $66.8 million in 1Q24[56] - AGAMREE revenue for 1Q25 was $30.4 million[56] - FYCOMPA revenue for 1Q25 was $35.6 million, compared to $22.0 million in 1Q24[56] - FIRDAPSE is projected to generate between $355 million and $360 million in revenue for 2025[60] - AGAMREE is projected to generate between $100 million and $110 million in revenue for 2025[60] - FYCOMPA is projected to generate between $90 million and $95 million in revenue for 2025[60] Market & Strategic Focus - The total addressable market for the LEMS population is estimated to be over $1 billion[29] - The total addressable market for the DMD population is estimated to be over $1 billion[39]

Catalyst Pharmaceuticals (CPRX) 2025 Conference May 14, 2025 11:00 AM ET Speaker0 Here with our next company presenter at the BofA Annual Healthcare Conference. I'm pleased to be introducing our next company presenter Catalyst Pharmaceuticals and Richard Ailey, President and Chief Executive Officer and Steve Miller, COO and CSO. My name is Jason Gerberry. I cover SpitCat Biotech and Specialty Pharma at BofA. And so Catalyst, a commercial stage rare orphan focused company in growth mode and has a sort of a l ...

Catalyst Pharmaceuticals (CPRX) reported adjusted earnings of 68 cents per share for the first quarter of 2025, beating the Zacks Consensus Estimate of 53 cents. The company had recorded adjusted earnings of 38 cents in the year-ago quarter.Total revenues, the majority of which comprised product revenues, amounted to $141.4 million in the reported quarter, representing growth of 44% year over year. The recorded figure also surpassed the Zacks Consensus Estimate of $130 million.Catalyst Pharmaceuticals’ top ...

Catalyst Pharmaceuticals (CPRX) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Michael Kalb - Executive VP & CFORichard Daly - President & CEOJeff Del Carmen - Executive Vice President, Chief Commercial OfficerBenjamin Paluch - Equity Research Senior Associate - BiotechCharles Duncan - Managing DirectorRohan Mathur - Biopharma Equity Research AssociateGary Ingenito - Chief Medical & Regulatory OfficerFelix Ampomah - Senior Associate Conference Call Participants Asim Rana - Equity Analys ...

Financial Data and Key Metrics Changes - Total net revenues increased by 43.6% year over year to $141,400,000, with significant contributions from all products [4][26] - Net income before income taxes for Q1 2025 was $71,300,000, a 145% increase year over year [28] - GAAP net income for Q1 2025 was $56,700,000, or $0.47 per basic share, reflecting a 144% increase year over year [28] - Non-GAAP net income for Q1 2025 was $86,600,000, or $0.71 per basic share, compared to $46,800,000 in Q1 2024 [28][29] Business Line Data and Key Metrics Changes - Firdapse generated revenue of $83,700,000, a 25.3% increase year over year [6][27] - Agamry's net product revenues totaled $22,000,000, compared to $1,200,000 in Q1 2024, marking its first full year of commercial availability [9][27] - Fycompa's net product revenue was $35,600,000, representing a year-over-year growth of 17.1% [11][28] Market Data and Key Metrics Changes - Approximately 20% to 25% of current Firdapse patients are cancer-associated LEMS patients, with expectations to increase this percentage through screening initiatives [49][90] - The market for LEMS is estimated at $1,200,000,000, with the company currently holding about 25% market penetration [94] Company Strategy and Development Direction - The company aims to expand its market leadership for Firdapse and Agamry while managing the transition of Fycompa post-patent expiry [12][15] - Strategic initiatives include enhancing patient access and focusing on business development opportunities that align with the company's goals [15][75] - The company is committed to advancing health equity by expanding access to therapies for underserved populations [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth momentum and achieving full-year revenue guidance of $545,000,000 to $565,000,000 [16][26] - The company is focused on executing strategic priorities and maintaining operational excellence [15][36] Other Important Information - The company ended Q1 2025 with cash and cash equivalents of $580,700,000, an increase from $517,600,000 at the end of 2024 [34] - Research and development expenses for Q1 2025 were $3,900,000, up from $2,600,000 in Q1 2024, reflecting ongoing investments in clinical studies [33] Q&A Session Summary Question: What contributed to Firdapse's growth this quarter? - Management indicated that approximately 15% to 20% growth is typical, and the strong performance in Q1 was partly due to recovery from the Change Healthcare incident [39][41] Question: What is the proportion of Fycompa patients on tablet versus oral suspension? - Approximately 85% of Fycompa patients are on the tablet formulation [44][62] Question: How is the uptake of Firdapse among small cell lung cancer patients? - Currently, 20% to 25% of LEMS patients on Firdapse are cancer-associated, with plans to increase this through screening efforts [49][90] Question: What are the company's current thoughts on business development? - The company remains focused on identifying immediately accretive opportunities and sees the current market dynamics as beneficial for its strategy [54][56] Question: How does the company plan to minimize brand erosion for Fycompa post-exclusivity? - Management noted that there is a tendency for anti-seizure medications to retain patients, which may help minimize brand erosion [70][72] Question: What is the company's market penetration for Firdapse? - The company estimates a market penetration of about 25% for Firdapse, with significant growth potential remaining [94][96]

Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be He ...

Catalyst Pharmaceuticals (CPRX) Q4 2024 Earnings Call February 27, 2025 08:30 AM ET Company Participants Michael Kalb - Executive VP & CFORichard Daly - President & CEOJeff Del Carmen - Chief Commercial OfficerGary Ingenito - Chief Medical & Regulatory OfficerBenjamin Paluch - Equity Research Senior AssociateRohan Mathur - Equity Research AssociateFelix Ampomah - Senior Associate Conference Call Participants Charles Duncan - AnalystPavan Patel - AnalystAsim Rana - Equity AnalystJoseph Catanzaro - Director & ...

Catalyst Pharmaceuticals (CPRX) Q4 2024 Earnings Call February 27, 2025 08:30 AM ET Company Participants Michael Kalb - Executive VP & CFORichard Daly - President & CEOJeff Del Carmen - Chief Commercial OfficerGary Ingenito - Chief Medical & Regulatory OfficerBenjamin Paluch - Equity Research Senior AssociateRohan Mathur - Equity Research AssociateFelix Ampomah - Senior Associate Conference Call Participants Charles Duncan - AnalystPavan Patel - AnalystAsim Rana - Equity AnalystJoseph Catanzaro - Director & ...